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Aim.T oc o m p a r et h ee ﬃcacy and safety of armodaﬁnil, the R-enantiomer of modaﬁnil, with modaﬁnil in patients of shift work
sleep disorder (SWSD).Material and Methods.Thiswasa12-week, randomized,comparative,double-blind, multicentric, parallel-
group study in 211 patients of SWSD, receiving armodaﬁnil (150mg) or modaﬁnil (200mg) one hour prior to the night shift.
Outcome Measures.E ﬃcacy was assessed by change in stanford sleepiness score (SSS) by at least 2 grades (responder) and global
assessment for eﬃcacy. Safety was assessed by incidence of adverse events, change in laboratory parameters, ECG, and global
assessment of tolerability. Results. Both modaﬁnil and armodaﬁnil signiﬁcantly improved sleepiness mean grades as compared to
baseline (P<. 0001). Responder rates with armodaﬁnil (72.12%) and modaﬁnil (74.29%) were comparable (P = .76). Adverse
event incidences were comparable. Conclusion. Armodaﬁnil was found to be safe and eﬀective in the treatment of SWSDin Indian
patients. The study did not demonstrate any diﬀerence in eﬃcacy and safety of armodaﬁnil 150 mg and modaﬁnil 200mg.
1.Introduction
A signiﬁcant proportion of employed individuals in India
work during night hours. This causes misalignment between
the sleep and wake propensities that are controlled by
hypothalamic circadian pacemaker [1] and results into shift
work sleep disorder (SWSD). The reported incidence of2 Neurology Research International
SWSD in India is about 44.8% of night-shift workers and
35.8% of rotating workers [2]. SWSD is characterized by
persistent excessive sleepiness during night work and insom-
nia when attempting sleep in the daytime [3]. Individuals
with SWSD have signiﬁcantly higher incidence of sleepiness-
relatedaccidents,absenteeism,depression,andmissedfamily
and social activities as compared with other night-shift
workers [2]. It is also associated with higher incidence of
ulcers, cardiovascular disease, and deﬁcit in cognition and
psychomotor performance [4, 5].
The pharmacological management of SWSD involves
treatment with modaﬁnil that has been shown to improve
wakefulness and ability to sustain attention in these patients.
However, despite the half-life of 15 hours, the wakefulness
promoting eﬀect of modaﬁnil is found to be ill-sustained in
the last one third of night shift hours [6]. The lack of eﬃcacy
in the early morning hours and undue patient conﬁdence in
thedrugcanresultintoexcessivesleepinesswhilecommuting
home. This can increase the chances of sleepiness-related
accidents. Armodaﬁnil, the chirally pure R-enantiomer of
modaﬁnil, approved by US FDA in 2007 has half-life (t1/2 =
15 hours) three times longer than its S-enantiomer (t1/2 = 3
hours) [7]. Despite the same half lives, comparison of the
equivalent (200mg) doses of modaﬁnil and armodaﬁnil, in
humans has revealedthat armodaﬁnil sustains higher plasma
concentrations 6–14hrs postadministration than that of
racemic modaﬁnil with longer maintenance of wakefulness
[8–10].
This was a randomized, comparative, double-blind, and
multicentricstudycomparingtheeﬀectsofmodaﬁnil 200mg
with armodaﬁnil 150mg in Indian patients of SWSD. To
our knowledge, this is the ﬁrst comparative study in SWSD
patients.
2.Materialsand Methods
2.1. Study Design and Approvals. Prior approval was
obtainedfromDrugControllerGeneralofIndia(DCGI)and
appropriate ethics committees. The study was conducted in
accordance of Good Clinical Practice guidelines (issued by
Central Drugs Standard Control Organization, Government
of India) and according to the Declaration of Helsinki.
The trial was registered at the Clinical Trials Registry, India
(http://www.ctri.in/).
2.2. Patients. After obtaining written informed consent,
patients of either sex, aged between 18 and 60 years,
attending outpatient clinics of the authors, and suﬀering
from excessive sleepiness associated with SWSD (assessed
basis patient’ primary complaint and using the diagnostic
criteria adopted from international classiﬁcation for sleep
disorders [3]( Table 1)) were enrolled. Patients were working
at least ﬁve night shifts every month for 12 hours or less,
with 6 hours or more working between 10p.m. and 8a.m.
and at least three shifts occurring consecutively. The major
exclusion criteria were patients with signiﬁcant liver or
kidney or heart diseases, patients with clinically signiﬁcant,
uncontrolled psychiatric or medical condition, patients with
known history of hypersensitivity to formulation, patients
operating an automobile or hazardous machinery, caﬀeine
consumption averaging more than 600mg/day within 1
week of baseline, use of other concomitant medications
which inhibit, induce, or are metabolized by CYP450,
patients using sedative or CNS acting drugs or medication
liable to aﬀect outcome of the study (e.g., antihistamines,
selective serotonin reuptake inhibitors, tricyclic antidepres-
sants, lithium, anti-psychotics, anticonvulsants, monoamine
oxidase inhibitor, benzodiazepines, psychostimulants, and
anticoagulants), pregnant and lactating mothers, females of
reproductive age and expecting pregnancy or using steroidal
contraception, and patients with alcohol or drug abuse.
2.3. Study Design and Medications. This was a multi-
centric, randomized, comparative, and double-blind par-
allel group, clinical trial conducted over 18 sites across
India. Randomization in blocks of ten was carried out
in 1:1 ratio for test and reference products online at
http://www.randomization.com/. Patients received orally
either armodaﬁnil 150mg tablet (Emcure Pharmaceuticals
Ltd., India) or modaﬁnil 200mg tablet (from commercial
source) one hour prior to start of every night shift for
12 weeks. Coprescriptions not interfering with the study
drug evaluation were allowed. The test formulation was
earlier found to be bioequivalent to the US FDA-approved
formulation of armodaﬁnil, in 26 healthy Indian volunteers
[11]. The tablets of armodaﬁnil and modaﬁnil were identical
in shape, size, and color and were dispensed in coded,
identical, and opaquepacks to conceal identity and maintain
blinding.
2.4. Eﬃcacy Assessment. Patients were evaluated for sleepi-
ness score based on Stanford sleepiness Scale (SSS) at
baseline, 4 weeks, 8 weeks, and 12 weeks [12]. All the
assessments were done in the morning hours at the end of
three consecutivenight shifts. The primary eﬃcacy endpoint
was proportion of patients showing at least 2 grades of
improvement (responder) based on SSS in both groups.
The other eﬃcacy variables included improvement in mean
SSS grades compared to baseline, compliance to therapy,
and patients’ as well as physicians’ global assessment for
eﬃcacy. Global assessment of eﬃcacy was performed using
the following grades: (i) excellent = reduction of >75% of
symptoms, (ii) good = reduction of 51–75% of symptoms,
(iii) fair = reduction of 26–50% of symptoms, and (iv)
poor = no improvement or reduction in <25% of symp-
toms. Patients’ compliance to the therapy was calculated in
percentage by using following formula: (number of tablets
actuallytaken×100)/numberoftabletssupposedtobetaken.
2.5. Safety Assessment. A general and detailed systemic
examination was performed for all patients during each
study visit. Blood samples were collected at baseline and at
the end of the study for complete hemograms, liver function
tests, renal function tests, lipid proﬁle, and fasting blood
glucose levels. Electrocardiograms were performed for all
patients at baseline and at the end of the study. TolerabilityNeurology Research International 3
Table 1
Diagnostic criteria for SWSD (adopted from ICSD criteria)3
(A) The patient has a primary complaint of insomnia or excessive sleepiness.
(B) The primary complaint is temporally associated with a work period (usually night work) that occurs during the habitual sleep phase.
(C) No medical or mental disorder accounts for the symptoms.
(D) The symptoms do not meet criteria for any other sleep disorder producing insomniaor excessive sleepiness (e.g., time-zone change
(jet lag) syndrome).
Minimal criteria: A plus B.
211 patients enrolled
105 patients
assigned to receive
armodaﬁnil
106 patients
assigned to receive
modaﬁnil
105 were included in
intention-to-treat
analysis
106 were included in
intention-to-treat
analysis
1 patient lost to
followup
1 patient lost to
followup
Figure 1: Study ﬂow chart.
was assessed by recording patients’ global assessment about
the tolerability of the drug and percent of the patients
experiencing any drug-related adverse events. The global
assessment of tolerability was performed using following
grades: (i) excellent = no adverse drug reaction, (ii) good =
mild adverse drug reaction but no interference with normal
lifestyle,(iii)fair =mildadversedrugreactionwhichinterfer-
ence with normal lifestyle. However, beneﬁtsof drug therapy
outweigh the inconvenience, (iv) poor = drug withdrawn.
2.6. Statistical Analysis. Prestudy calculations showed that a
sample size of 100 in each group would have 80% power to
detectadiﬀerenceofatleast19%inresponderratewithasig-
niﬁcance level (alpha) of.05 (two tailed). Demographic and
baseline characteristics were summarized using descriptive
statistics. Proportions were compared using Fischer’s exact
test. Within group and between-groups comparisons were
done using t-test. Global assessment for eﬃcacy and toler-
ability was done by comparing the proportion of patients
showing excellent and good response against proportion of
patients showing fair and poor response. For all statistical
tests, a P value of less than or equal to 0.05 was considered
as signiﬁcant, after correction for any multiple comparisons.
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Figure 2: Improvement in Stanford sleepiness scale. ∗P<. 0001
at 12 wks versus baseline for both modaﬁnil and armodaﬁnil using
paired t test; n.s.: not signiﬁcant intergroup diﬀerences at baseline,
4, 8, and 12 weeks using unpaired t-test.
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Figure 3: Physicians’ and patients’ assessment of eﬃcacy. Patients
with good and excellent response in armodaﬁnil group were
compared against those in modaﬁnil group using Fischer exact test;
n.s.—not signiﬁcant; (excellent—reduction of >75% of symptoms,
good: reduction of 51–75% of symptoms, fair: reduction of 26–
50% of symptoms, poor: no improvement or reduction in <25%
of symptoms).
3.Results
Two hundred and eleven patients of SWSD were recruited
with 105 subjects in armodaﬁnil group and 106 subjects in
the modaﬁnil group (Figure 1). The baseline demographic4 Neurology Research International
Table 2: Baseline and demographic parameters.
Parameter Armodaﬁnil group Modaﬁnil group P
Number of patients 105 106 NA
Age in years (Mean ± SD) 32.15 ± 10.25 31.90 ± 9.35 .85
Weight (Kg) (Mean ± SD) 60.88 ± 11.43 61.09 ± 11.33 .52
Male: female 81:24 90:16 .16∗
Total number of months working in night shift (mean ± SD) 44.44 ± 119.53 36.41 ± 42.10 .52
Systolic BPmmHg (mean ± SD) 122.83 ± 9.67 123.39 ± 11.38 .70
Diastolic BPmmHg (mean ± SD) 78.83 ± 6.75 78.16 ± 7.16 .49
All statisticaltestswere unpaired t-test except for the ∗ = Fisher’s exact test; P<. 05 = statisticallysigniﬁcant. NA: Not applicable.
Table 3: Intention-to-treat analysis of adverse events in 211 patients.
Armodaﬁnil n (%) Modaﬁnil n (%) P
Cardiovascular
Palpitation 6 (5.71) 9 (8.49) .59
Hypertension 4 (3.81) 8 (7.55) .37
A n g i n a 0( 0 ) 0( 0 ) N A
Dermatologic
Skin rash 1 ( 0.95) 0 (0) .48
Contact dermatitis 0 (0) 0 (0) NA
Gastrointestinal
Nausea 13 (12.38) 11 (10.38) .67
Vomiting 1 (0.95) 2 (1.89) 1.00
Dry mouth 15 (14.29) 19 (17.92) .58
Dyspepsia 6 (5.71) 9 (8.49) .59
Constipation 11 (10.48) 5 (4.72) .13
Abdominal pain 4 (3.81) 5 (4.72) 1.00
Diarrhea 0 (0) 4 (3.77) .12
Psychiatric
Insomnia 5 (4.76) 11 (10.38) .20
Anxiety 7 (6.67) 9 (8.49) .80
Depression 2 (1.90) 0 (0) .25
Agitation 3 (2.86) 6 (5.66) .50
Nervousness 10 (9.52) 4 (3.77) .10
Depressed mood 4 (3.81) 0 (0) .06
Neurological
Dizziness 2 (1.90) 8 (7.55) .10
Disturbance in attention 3 (2.86) 2 (1.89) .68
Tremor 3 (2.86) 7 (6.60) .33
Headache 14 (13.33) 15 (14.15) 1.00
Migraine 1 (0.95) 0 (0) .48
Paraesthesia 0 (0) 0 (0) NA
General
Fatigue 4 (3.81) 4 (3.77) 1.00
Thirst 12 (11.43) 6 (5.66) .15
Inﬂuenza like illness 0 (0) 0 (0) NA
Fever 1 (0.95) 0 (0) .48
Total no. of patients with adverse events 45 ( 42.85) 43 (40.57) .78
Fisher’s exact test; P<. 05 = statisticallysigniﬁcant.Neurology Research International 5
Excellent
Good
Fair
Poor
0
10
20
30
40
50
60
70
Physician
tolerability for
armodaﬁnil
Physician
tolerability for
armodaﬁnil
Physician
tolerability for
modaﬁnil
Physician
tolerability for
modaﬁnil
(
%
) n.s.
n.s.
Figure 4: Physicians’ and Patients’ Assessment of Tolerability.
Patients with good and excellent response in armodaﬁnil group
were comparedagainstthoseinmodaﬁnilgroupusingFischerexact
test; n.s.: Not signiﬁcant; (Excellent: No Adverse drug reaction,
Good: Mild Adverse drug reaction. No interference with normal
lifestyle, Fair: Mild Adverse drug reaction which interference with
normal lifestyle. Beneﬁt outweighs inconvenience, Poor: Drug
withdrawn).
parameters of both groups were comparable (Table 2). Both
modaﬁnil and armodaﬁnil signiﬁcantly improved sleepiness
grades as compared to baseline (P<. 0001) (Figure 2).
Responder rates with armodaﬁnil (72.12%) and modaﬁnil
(74.29%) were comparable (P = .76). At the end of therapy,
compliance in both modaﬁnil group (99.31% ± 3.06%)
and armodaﬁnil group (99.13% ± 2.35%) was found to
be good and comparable (P = .63) indicating adequate
patient adherence to therapy. Both physicians’ and patients’
assessment of eﬃcacy was found to be comparable between
armodaﬁnil and modaﬁnil group (Figure 3). The intention-
to-treat analysis showed that the adverse event incidences in
modaﬁnil (40.57%) and armodaﬁnil (42.87%) groups were
similar (P = .78).
The adverse eﬀect proﬁle of both drugs was found to
be similar with headache, nausea, and dry mouth being the
common adverse eﬀects (Table 3). There were no serious
adverse events reported during the study. No adverse eﬀects
on cognitive or psychomotor functions reported during the
study. No incidences of accidents or absenteeism from work
were noted during the study period as assessed from patient
history. Physicians’ and patients’ assessment of tolerability
was found to be comparable between armodaﬁnil and
modaﬁnil group (Figure 4). The baseline and after-therapy
biochemical values were within normal range and similar
between two groups, except that there was slight increase in
mean SGPT in both armodaﬁnil and modaﬁnil groups as
compared to baseline (P = .008 and .0007) without inter-
groupsigniﬁcance and mean bloodureavaluein armodaﬁnil
group increased (P = .002) compared to baseline. However,
the increased values were within normal limits. In both
groups, electrocardiograms were within normal at baseline
and after completion of therapy in all patients. One patient
in each group opted to discontinue therapy due to adverse
events. The adverse events that led to discontinuation were
palpitation, anxiety, hypertension, depression, nervousness,
and depressed mood in a patient receiving armodaﬁnil and
vomiting along with dizziness in another patient receiving
modaﬁnil.
4.Discussion
The present study conﬁrms the eﬃcacy of armodaﬁnil
150mg in patients of SWSD. The eﬃcacy of armodaﬁnil
was found to be comparable to 200mg of modaﬁnil in
maintaining wakefulness. The safety proﬁle of armodaﬁnil
was found to be similar to modaﬁnil. Both modaﬁnil and
armodaﬁnil caused a slight increase in liver enzymes, and
armodaﬁnil caused a slight increase in blood urea nitrogen.
This was not of clinical signiﬁcance as the increased values
were within normal laboratory limits [13]. Armodaﬁnil
150mg was comparable to modaﬁnil 200mg, which indi-
cates that armodaﬁnil is 1.33 time more potent than racemic
modaﬁnil. The use of R-enantiomer of modaﬁnil avoids
unnecessary use of S-isomer and exerts less metabolic load
on the body.
In previous studies, 200mg of armodaﬁnil was shown to
providemoresustainedplasma concentrationslatein theday
as comparedto 200mg ofmodaﬁnil and monophasic plasma
elimination kinetics as compared biphasic for modaﬁnil [8].
This was due initial faster elimination of the S-isomer of
modaﬁnil. This pharmacokinetic advantage was claimed to
translate into therapeutic beneﬁt. We chose the 150mg dose
of armodaﬁnil, as this was the approved dosage for the
present indication. Our study demonstrated no diﬀerence
in the eﬃcacy of 150mg of armodaﬁnil over 200mg of
modaﬁnil.Thecomparativeeﬃcacyof200mgofarmodaﬁnil
with modaﬁnil in SWSD has not yet been assessed.
A limitation of the present study is that the assessment
of sleep latency and polysomnography throughout the
nightshift could not be done due to unavailability of patients
and investigators. This prevented assessment of the clinical
correlates of pharmacokinetic advantages of armodaﬁnil [7].
5.Conclusion
Armodaﬁnil was found to be safe and eﬀective in the
treatment of SWSD. The study did not demonstrate any
diﬀerence in eﬃcacy and safety between armodaﬁnil 150mg
and modaﬁnil 200mg, and both drugs were comparable.
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